A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect-Reference-Cited by-同舟云学术

A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: An integrated genomics approach reveals a wide gene dosage effect

Published:2009-07 Issue:7 Volume:48 Page:603-614
ISSN:1045-2257
Container-title:Genes, Chromosomes and Cancer
language:en
Short-container-title:Genes Chromosom. Cancer

Author:

Agnelli Luca,Mosca Laura,Fabris Sonia,Lionetti Marta,Andronache Adrian,Kwee Ivo,Todoerti Katia,Verdelli Donata,Battaglia Cristina,Bertoni Francesco,Deliliers Giorgio Lambertenghi,Neri Antonino

Publisher

Wiley

Subject

Cancer Research,Genetics

Reference38 articles.

1. Molecular classification of multiple myeloma: A distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations;Agnelli;J Clin Oncol,2005

2. Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma;Agnelli;Haematologica,2007

3. Upregulation of translational machinery and distinct genetic subgroups characterise hyperdiploidy in multiple myeloma;Agnelli;Br J Haematol,2007

4. Uniparental disomies, homozygous deletions, amplifications and target genes in mantle cell lymphoma revealed by integrative high-resolution whole genome profiling;Bea;Blood,2009

5. Molecular pathogenesis and a consequent classification of multiple myeloma;Bergsagel;J Clin Oncol,2005

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma;Cancer Cell;2024-07

2. Section E6.1–6.6 of the American College of Medical Genetics and Genomics (ACMG) Technical Laboratory Standards: Cytogenomic studies of acquired chromosomal abnormalities in neoplastic blood, bone marrow, and lymph nodes;Genetics in Medicine;2024-04

3. Che-1/miR-590-3p/TAZ axis sustains multiple myeloma disease;Leukemia;2024-02-17

4. CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1;Leukemia;2023-10-28

5. The selective activator protein-1 inhibitor T-5224 regulates the IRF4/MYC axis and exerts cooperative antimyeloma activity with bortezomib;Chemico-Biological Interactions;2023-10